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Abstract
Introduction: In Sjögren’s syndrome, keratoconjunctivitis sicca (dry eye) is associated with infiltration of lacrimal
glands by leukocytes and consequent losses of tear-fluid production and the integrity of the ocular surface. We
investigated the effect of blockade of the lymphotoxin-beta receptor (LTBR) pathway on lacrimal-gland pathology
in the NOD mouse model of Sjögren’s syndrome.
Methods: Male NOD mice were treated for up to ten weeks with an antagonist, LTBR-Ig, or control mouse
antibody MOPC-21. Extra-orbital lacrimal glands were analyzed by immunohistochemistry for high endothelial
venules (HEV), by Affymetrix gene-array analysis and real-time PCR for differential gene expression, and by ELISA for
CXCL13 protein. Leukocytes from lacrimal glands were analyzed by flow-cytometry. Tear-fluid secretion-rates were
measured and the integrity of the ocular surface was scored using slit-lamp microscopy and fluorescein
isothiocyanate (FITC) staining. The chemokine CXCL13 was measured by ELISA in sera from Sjögren’s syndrome
patients (n = 27) and healthy controls (n = 30). Statistical analysis was by the two-tailed, unpaired T-test, or the
Mann-Whitney-test for ocular integrity scores.
Results: LTBR blockade for eight weeks reduced B-cell accumulation (approximately 5-fold), eliminated HEV in
lacrimal glands, and reduced the entry rate of lymphocytes into lacrimal glands. Affymetrix-chip analysis revealed
numerous changes in mRNA expression due to LTBR blockade, including reduction of homeostatic chemokine
expression. The reduction of CXCL13, CCL21, CCL19 mRNA and the HEV-associated gene GLYCAM-1 was confirmed
by PCR analysis. CXCL13 protein increased with disease progression in lacrimal-gland homogenates, but after LTBR
blockade for 8 weeks, CXCL13 was reduced approximately 6-fold to 8.4 pg/mg (+/- 2.7) from 51 pg/mg (+/-5.3) in
lacrimal glands of 16 week old control mice. Mice given LTBR blockade exhibited an approximately two-fold
greater tear-fluid secretion than control mice (P = 0.001), and had a significantly improved ocular surface integrity
score (P = 0.005). The mean CXCL13 concentration in sera from Sjögren’s patients (n = 27) was 170 pg/ml,
compared to 92.0 pg/ml for sera from (n = 30) healthy controls (P = 0.01).
Conclusions: Blockade of LTBR pathways may have therapeutic potential for treatment of Sjögren’s syndrome.
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Introduction
Sjögren’s syndrome is an autoimmune exocrinopathy
affecting most secretory glands, but especially the salivary
and lacrimal glands. As the disease progresses, leukocytes
accumulate in salivary and lacrimal glands. This results
in hypo-secretion of saliva and tear fluids causing xeros-
tomia or dry mouth and keratoconjunctivitis sicca (KS)
or dry eye, respectively. The infiltrating lymphocytes in
salivary gland biopsies are often organized into tertiary
lymphoid tissues (TLT) with segregated T- and B-cell
zones and follicular dendritic cell (FDC) networks [1].
Some of the TLT are engaged in germinal center
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reactions, evidenced by expression of activation-induced
cytidine deaminase (AID) [1,2], although one report indi-
cates active germinal center reactions may be relatively
rare [3]. Whether the immune reactions that occur
within TLT exert harmful or beneficial effects is not yet
clear. Experimental evidence exists for both possibilities,
suggesting that the effects of immune reactions in TLT
vary with organ and disease context [4].
The lymphotoxin-beta receptor (LTBR) pathway has
been associated with the presence of TLT (or ectopic folli-
cles) at sites of chronic inflammation in several autoim-
mune diseases [4,5]. LTBR directly controls several gene
products that contribute to tertiary lymphoid tissue devel-
opment, including homeostatic chemokines (CCL19,
CCL21, CXCL13) and several proteins required for per-
ipheral lymph node addressin (PNAd) assembly on high-
endothelial venules [6,7]. Therefore, CXCL13 and the lym-
photoxin-beta receptor pathway are considered essential
to development of tertiary lymphoid tissues and might
constitute a useful therapeutic target in certain diseases
[4,7-9]. In minor salivary gland biopsies from patients with
Sjogren’s syndrome, lymphotoxin-beta was the fifth most
differentially expressed gene, with expression approxi-
mately eight fold higher than in gland biopsies from
healthy control subjects [10]. LTBR is expressed in epithe-
lium of salivary glands in mouse embryos from day 16.5
onward; expression in lacrimal glands has not yet been
formally documented [11]. Interestingly, CXCL13 also was
one of only five genes expressed in >90% of the Sjogren’s
patient biopsies (but <10% of control biopsies) and
CXCL13 expression has been localized to ectopic follicles
in salivary glands in Sjogren’s syndrome, making its
expression in salivary glands a possible disease marker
[1,12].
In murine models of the disease, as in humans, Sjögren’s
syndrome occurs both as a primary disease and as a sec-
ondary disease associated with autoimmune diseases such
as lupus, scleroderma, diabetes and rheumatoid arthritis
[13]. For example, the female NOD mouse that is often
used to study the salivary gland aspects of Sjögren’s syn-
drome also develops diabetes concurrent with salivary
gland pathology. The salivary gland disease in female
NOD mice is not dependent on the diabetes however [14].
Each disease derives from unique chromosomal regions
(salivary gland disease versus diabetes) with one chromo-
somal region containing the genes that cause diabetes and
a different chromosomal region encoding the salivary
gland disease [15]. The two regions have been physically
separated and when one region was bred into an autoim-
mune resistant strain, it resulted in a transgenic mouse
with Sjögren’s-like salivary gland disease but without pan-
creatitis or diabetes [15]. In this regard, NOD mice argu-
ably may be viewed as a model of primary Sjögren’s
syndrome [15]. While salivary gland pathology is
prominent in female NOD mice, their lacrimal glands
remain virtually unaffected. Therefore, female mice cannot
be used as a model of the dry-eye disease, or keratocon-
junctivitis sicca (KS), of Sjögren’s syndrome,.
Less is understood about lacrimal gland pathology in
Sjögren’s syndrome than salivary gland pathology, lar-
gely due to the difficulty of obtaining biopsies of lacri-
mal glands compared to salivary glands. However, it is
known that large leukocyte infiltrates form in lacrimal
glands of patients with Sjögren’s syndrome. Very similar
leukocyte infiltrates develop in the lacrimal glands of
male NOD mice used in this study, with coincident
losses in gland secretory function [16-18]. Because of
this, male NOD mice provide a useful model of dry-eye
disease or KS. Recently, the male NOD mouse model
was thoroughly characterized to illustrate fully its poten-
tial as a model of KS [19,20]. In contrast with female
mice, male NOD mice rarely develop salivary gland dis-
ease or diabetes (approximately 10%), however very
large leukocyte infiltrates spontaneously develop in their
lacrimal glands at an early age, offering an ideal and
practical model with which to investigate possible thera-
pies for the KS component of Sjögren’s syndrome
[21,22].
Leukocyte infiltrates develop in essentially 100% of the
lacrimal glands of male NOD mice starting as small, peri-
vascular infiltrates first observed at about 5 weeks of age.
By approximately 12 weeks of age, very large leukocyte
infiltrates are formed along with high endothelial venules
(HEV), that can be identified by immunoreactivity with
the monoclonal antibody MECA-79 that recognizes
PNAd [22]. An earlier study indicated that the HEV in
diseased lacrimal glands capture leukocytes from the cir-
culation and therefore HEV might be a very useful thera-
peutic target in Sjögren’s syndrome [22]. Since the
formation and maintenance of functional HEV in second-
ary lymphoid organs of mice is regulated by the LTBR
axis [6], as well as in TLT in experimental disease models
[7,8,23], LTBR is a novel therapeutic target in Sjögren’s
syndrome.
In this study, we tested the chimeric antagonist LTBR-
Ig, as a possible long-term therapeutic reagent (8-10 week
treatments) for KS in Sjogren’s syndrome. Blockade of the
LTBR-pathway for 8 weeks reduced the size of lymphocyte
aggregates, blunted homeostatic chemokine expression
(CXCL13 and CCL19) by approximately 2- to 5- fold and
reduced by up to 30-fold the expression of HEV-related
genes (GLYCAM-1 and carbohydrate (N-acetylglucosa-
mine 6-O) sulfotransferase 4 (Chst4)) in lacrimal glands.
Antagonism of the LTBR-pathway thus undermined HEV
development and function, dramatically reducing the size
of leukocyte infiltrates in lacrimal glands, and mediated a
partial protection from losses in the secretion of tear-fluids
and the integrity of the ocular surface.
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Materials and methods
Chemicals and antibodies
Pilocarpine was purchased from Sigma (St. Louis, MO,
USA). Collagenase D used for tissue digestion for flow
cytometry (FACS) analysis was purchased from Roche
Applied Sciences (Indianapolis, IN, USA). A 15-minute
digestion at room temperature with this type of collage-
nase did not affect the ability to detect relevant antigens
on lymphocytes by flow-cytometry (B220, CD3, CD4,
CD11c, CD23, CD21, CD45) (data not shown).
Conjugated antibodies for FACS analyses were pur-
chased from BD Pharmingen (San Diego, CA, USA). In
some experiments, a custom conjugated cocktail of antibo-
dies (Jeff Browning, Biogen/Idec, Cambridge, MA, USA)
was used for ten-color B-cell, T-cell and DC phenotyping.
MECA-79 (rat IgM) for PNAd staining in paraffin and
frozen tissues was from BD Pharmingen and was devel-
oped with secondary horseradish peroxidase (HRP)-conju-
gate (goat-anti-rat IgM) from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA). Anti-B220 and anti-
CD3 for paraffin staining (rat anti-mouse B220 Cat#
1258G; rat anti-human/mouse CD3 Cat# MCA1477) were
purchased from Serotec (Raleigh, NC, USA) and was devel-
oped with Vector ABC Horseradish Peroxidase Kit.
Patient sera
Sera from 27 patients with primary Sjögren’s syndrome
who were being followed in the Rheumatology Depart-
ment of General Hospital of Athens, Athens, Greece and
30 healthy controls were analyzed for CXCL13 protein
levels. The diagnosis of primary Sjögren’s syndrome was
based on previously published criteria [24]. All patients
and controls provided informed consent prior to participa-
tion to the study. Determination of CXCL13 protein levels
was performed with a solid phase ELISA kit according to
the manufacturer’s instructions (Human CXCL13/BLC/
BCA-1 Quantikine ELISA Kit; R&D Systems, Minneapolis,
MN, USA). The mean age of Sjögren’s syndrome patients
was 57.17 +/- 10.10 years, and for controls was 57.55 +/-
21.17 years. There was one man in each group.
Mice and treatments
The local VA Medical Center Institutional Animal Care
and Use Committee approved all experiments and experi-
mental procedures performed in this study and all mice
were housed in an Association for Assessment and
Accreditation of Laboratory Animal Care accredited facil-
ity. All male and female NOD mice were purchased from
Taconic (Germantown, NY, USA). Male mice were
received when they were 5 to 6 weeks old and female mice
when they were 7 weeks old. The systemic antagonist,
mLTBR-mIgG1 (LTBR-Ig) and a control murine mono-
clonal IgG1 antibody MOPC-21 were prepared at Biogen/
Idec and stored at -80°C until used. In all experiments
intra-peritoneal injections of 100 μg of either substance
were performed once a week. Unless indicated, all data
shown are representative of at least three independent
experiments, executed over a period of four years with
NOD mice from one vendor. The dose and injection regi-
men for LTBR-Ig is known to elicit maximal biologic
effects in other autoimmune animal models [6,25] and was
confirmed in experiments with NOD mice [26]. Efficacy
was confirmed in male NOD mice by the depletion of
splenic marginal zone B-cells after as long as 10 weeks of
injections of LTBR-Ig (data not shown).
Histochemistry, immuno-histochemistry and
morphometry
Organs were fixed with 10% formalin and embedded in
paraffin by standard methods or were embedded without
fixation in Optimal Cutting Temperature (OCT) embed-
ding compound for frozen sections. To quantify the
PNAd-stained HEV content of lacrimal glands, a series of
paraffin embedded tissue sections was prepared from
eight lacrimal glands (four mice) per treatment group
and sections were stained with MECA-79 monoclonal
and anti-rat-IgM-HRP and slides developed with dia-
mino-benzidine (DAB) as substrate. Randomly chosen
fields (n = 20) were photographed with a Zeiss bright-
field microscope and for each microscopic field, the area
stained with DAB (the HEV area) and the total area of
the gland was measured with NIH-Image software (5
fields/mouse). The mean and standard deviation of the
percent of the area of HEV relative to the total area was
then computed. For frozen sections, lacrimal glands were
bisected longitudinally to optimize OCT infiltration and
adhesion to slides (Fisher PLUS). Organs were kept
approximately 5 minutes at room temperature in OCT
compound, then frozen on dry ice and stored at -20°C
until sectioned. Sections of 10 μm thickness were air
dried for 30 minutes, fixed for 15 seconds with -20°C
acetone, and then air dried overnight before immunos-
taining. Immunofluorescent microscopy was performed
with a Nikon Eclipse 80i with a monochrome Retiga EXi
CCD camera to enhance sensitivity and pseudocolor
image capture and analysis with Nikon Elements soft-
ware. Custom, narrow band filters for Texas red and Cy5
were used for overlay of multi-color images. Quantitation
of PNAd staining was performed with a Zeiss Axioskop
brightfield scope with SPOT software for image capture
and NIH Image software for analysis.
Differential gene expression analysis and quantitiation
Mice were euthanized by carbon dioxide inhalation. With
the aid of a Zeiss surgical microscope cervical lymph
nodes were carefully dissected away from submandibular
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glands and the combined cervical nodes and combined
submandibular/salivary/parotid glands snap frozen on
dry ice. Each lacrimal gland was dissected; both glands
were combined from each of four mice and snap frozen
(four biological replicates). Where noted, single lacrimal
glands were snap-frozen for PCR while the contra-lateral
gland was used for FACS analysis. Total mRNA was iso-
lated from each sample with Trizol according to manu-
facturer instructions and DNase treated (DNA-free kit,
Ambion, Austin, TX, USA), quantitated using the Nano-
drop (Nanodrop Technologies, Wilmington, DE, USA)
and the quality was assessed using the Agilent 2100 Bioa-
nalyzer (Agilent Technologies, Palo Alto, CA, USA).
Reverse transcription to prepare cDNA was performed
using the M-MLV system, Invitrogen, Frederick, MD,
USA.
Preliminary real-time PCR analyses (CXCL13, CCL21,
CCL19, GAPDH) were performed with primer sets and
SYBR Green master mix from SA Biosciences (Frederick,
MD, USA), using a Bio Rad iQ5 iCycler with associated
software (data not shown). Quantification was computed
relative to target gene expression levels in healthy lacrimal
gland from 20 week old female NOD mice. Data obtained
by multiplex real time PCR analysis, shown in Results, was
performed using Taqman primer sets (CXCL9, CXCL12,
CXCL13, CCL19, CCL20, CCL21a, Chst2, Chst4, Gly-
CAM-1, VCAM, MAdCAM) from ABI using the Applied
Biosystems 7900HT PCR System (Carlsbad, CA, USA).
Target gene quantification (n = 7) was computed relative
to the mean (n = 4) gene expression levels in healthy lacri-
mal glands from 20 week old female NOD mice.
Gene transcription profiling was carried out with Mouse
Genome 430 2.0 arrays. All data processing and analysis
were done using R and BioConductor packages [27].
Probe intensities in the whole set were normalized using
the GCRMA (GC-corrected Robust Multi-Array Analysis)
method. Four replicate samples were available for each tis-
sue type, time point in the disease course and treatment
versus control. First, genes present in at least two samples
belonging to each group were identified. Second, gene
expression values were estimated in each group using lin-
ear models as implemented by the limma package. We
have identified differentially expressed genes between two
sample groups using linear models (limma package), t-sta-
tistic, and Bayesian log-odds posterior probabilities. Genes
with fold changes greater than 2 and Bayesian posterior
probabilities less then 0.05 were selected as significantly
differentially expressed between the groups. The data
obtained for each Affymetrix array can be found at Acces-
sion Number: [GEO:GSE32681][28].
CXCL13 ELISA of lacrimal-gland homogenates
Mouse organs collected for homogenization were quickly
weighed and then snap frozen with dry ice and stored at
-80 μC until used. Homogenates were prepared by thaw-
ing the tissue (approximately 10 to 20 mg) in 300 μl of
ice-cold RIPA (radio-immuno-precipitation assay) buffer
containing a cocktail of protease inhibitors and then
homogenizing on ice for at least 60 seconds with a Poly-
tron generator. The homogenates were centrifuged for 5
minutes at 13,000 RPM in a bench-top microfuge, the
clarified supernatant solution collected, the total volume
recorded and aliquots frozen for ELISA analysis. Mouse
CXCL13 ELISA was performed using R&D Systems Quan-
tikine kit after first determining that the presence of 50 μl
radioimmuno-precipitation assay (RIPA) buffer did not
significantly alter the ELISA assay. The volume of RIPA-
buffer for homogenization was empirically determined to
allow analysis of CXCL13 extracted from lymph nodes or
lacrimal glands with 50 μl or less of homogenate (that is, 5
to 70 pg/mg tissue of CXCL13 in 50 μl of homogenate).
The content of CXCL13 protein was determined for each
individual lacrimal gland from groups of mice treated with
LTBR-Ig from 8 to 16 weeks of age (n = 6) or untreated
mice (n = 4), and the mean and standard deviation
determined.
CFSE-labeled lymphocyte uptake by lymph nodes and
lacrimal glands
Carboxy-fluorescein-succinimidyl ester (CFSE) -labeled
lymphocytes were prepared from cells pooled from 6
spleens and 12 cervical lymph nodes isolated from 6-
week-old male donor NOD mice on the day of injection
(CFSE-Cell Trace kit from Invitrogen). To enrich the
CSFE-labeled cells for naïve cells (CD62L positive), the
NOD donor mice were first injected with 150 μg of anti-
CD40-ligand monoclonal antibody (MR-1), 5 days before
isolation of spleens and lymph node cells for CFSE-fluor-
escence-labeling. MR-1 antibody depletes activated lym-
phocytes and approximately 40% of the CFSE-labeled
donor lymphocytes used expressed CD62-L (data not
shown). The ratio of T and B cells in the input cells was
approximately 2:1. To label cells with CFSE, the pooled
cells were incubated for 14 minutes at 37 μC with CFSE at
100 nM in 20 ml of Ca++ and Mg++-free Hank’s balanced
salt solution, washed and suspended at 150 × 106/ml. Reci-
pient mice (five per treatment group) were given intrave-
nous injections of 30 × 106 CFSE-labeled cells. Preliminary
experiments indicated 20 hours was the minimum time
required to reliably quantify CFSE-cells in lacrimal-gland
infiltrates by flow-cytometry (data not shown).
Twenty hours after intravenous injection of CFSE-
labeled cells, each pair of lacrimal glands was minced with
micro-scissors 120 times, crushed between frosted-glass
microscope slides, and the dispersed cells filtered through
Falcon 70 μm mesh filters, washed and re-suspended in
FACS-buffer. Lymph nodes were not minced. The isolated
cells were stained with a multicolor antibody cocktail
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containing anti-CD45, anti-CD3, anti-CD4, anti-B220 and
anti-CD62L and analyzed on a BD FACS Canto flow-
cytometer. The total yield of leukocytes isolated from
lacrimal glands was determined by trypan blue stain and
counting by hemocytometer. This experiment was per-
formed twice.
To calculate the uptake rate of circulating CFSE-labeled
cells into lacrimal glands or nodes, 5 × 105 events were
collected for the combined pair of lacrimal glands from
each mouse (n = 5 mice of each treatment group). Initial
gating was on CD45 positive cells to distinguish leukocytes
from epithelial cells, nuclei and other debris in the homo-
genized glands. Note that CFSE cells entering lacrimal
glands would be immediately diluted to a greater extent by
the resident lymphocytes present in the glands of MOPC-
21-treated mice than LTBR-Ig-treated mice; that is, there
were always 3- to 4-fold more lymphocytes in glands of
MOPC-21-treated mice than LTBR-Ig-treated mice. Speci-
fically, for the experiment shown in the Results section
there were 4.33 times more lymphocytes in the lacrimal
glands of the MOPC-21-treated mice than in the LTBR-
Ig-treated mice. The uptake rate per hour of CFSE-labeled
cells into lacrimal glands or nodes was calculated and
plotted per 106 CD45-positive cells.
Determination of tear-flow rate
Tear-flow rates were determined both without, and with
pharmacologic stimulation by intraperitoneal injection of
pilocarpine, an agonist of parasympathetic nerve-pathways.
Specifically, the method used for measuring the unstimu-
lated tear-flow rate was a modification of a published pro-
cedure [29]. In brief, mice were anesthetized with
isofluorane, and before beginning the measurement the
end of a Zone-Quick phenol-impregnated thread was
placed under the lower eyelid near the medial canthus for
10 seconds to absorb any previously secreted tear-fluid.
The measurement was then begun by insertion of a sec-
ond fresh Zone-Quick thread under the eyelid, which
absorbed the tear-fluid secreted for 30 seconds. The length
of wetted thread was measured. The means and standard
deviations were determined and plotted, and two-tailed T-
test performed.
To measure the pilocarpine-stimulated tear flow-rate,
mice were weighed and injected with 0.5 mg/kg pilocarpine
and anesthetized throughout the procedure by inhalation
of isofluorane. Pilocarpine reaches a peak concentration in
the circulation within 5 minutes post-injection that is
maintained for about 10 minutes, declining afterward as
the drug is metabolized. The tear-fluid that had accumu-
lated under the eyelid during the first 5 minutes after injec-
tion of pilocarpine was first removed, and then the
quantification of tear-flow was begun by insertion of a
fresh Zone-Quick thread under the eyelid. Periodically dur-
ing the 10-minute collection period, after approximately 10
mm of thread was wetted, the tear-saturated threads were
removed and a fresh thread inserted. The total length of
wetted thread was recorded for each eye and the mean of
the lengths and standard deviations were calculated. The
data shown are representative of three experiments.
Scoring the integrity of ocular surface by slit-lamp
microscopy
The integrity of the ocular surface was determined after
FITC-staining, by examination of the eyes through a slit-
lamp microscope (adapted for mice) using illumination
with a Cobalt Blue filter. This adapted clinical method has
been used previously for mice [30]. After lightly anesthe-
tizing a mouse with isofluorane, 5 μl of a 0.03% solution of
FITC in sterile PBS was placed onto the surface of the eye,
and the lids manually opened and closed once. The mouse
was then allowed to awaken for 2 minutes to naturally
blink, then anesthetized again and the eye examined thor-
oughly (approximately 5 minutes) with Cobalt-Blue illumi-
nation with the mouse resting on a stage of the slit-lamp
microscope. While under anesthesia, the eye of the mouse
moves around slowly during the examination; therefore,
the entire surface of the eye can be examined and given a
score, based on a scale of 0 (no lesions) to 4 (see Addi-
tional file 6 for examples). The cornea was defined as the
most central area above the pupil (limbus to limbus) and
the conjunctiva as the remaining surface of the eye. This
experiment was performed 3 times, with the observer
blinded to treatment groups and 35 mice were examined
overall. The score for each eye is displayed in a scatter-
plot for a representative experiment, along with a mean
standard deviation. Statistical analysis was by Mann-Whit-
ney for non-parametric data sets.
Results
LTBR blockade reduces lymphocyte infiltration of lacrimal
glands
Eight week-old male NOD mice were treated for 8
weeks with a systemic LTBR-axis antagonist, LTBR-Ig.
Representative examples of leukocyte infiltrates in lacri-
mal glands of 16 week-old mice are shown in the very
low magnification photomicrographs of tissue sections
of whole glands (H+E stain) in Figure 1a-c, and a typical
infiltrate is shown at much higher magnification in
Additional File 1a. The leukocytes are tightly clustered
and are visible in Figure 1a and 1b, as areas of dark-
blue stained nuclei (examples marked by arrows). Com-
pared to untreated mice and control MOPC-21 treated
mice the clusters of leukocytes were greatly reduced in
size and number by treatment of mice for 8 weeks with
LTBR-Ig, as illustrated in Figure 1c. Massive leukocyte
aggregations were present in the lacrimal glands of the
oldest mice we examined (one year old), one example of
which is shown in Additional File 1b. It was of interest
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Figure 1 Number of leukocytes in lacrimal glands is reduced by treatment with LTBR-Ig. Representative photomicrographs of hematoxylin
and eosin stained paraffin tissue-sections (a to c) and tissue-sections stained with anti-B220 and immuno-peroxidase (dark brown) (d to h) from
NOD mice that were not treated (NT) or were treated from 8 to 16 weeks of age with MOPC-21 control antibody or with LTBR-Ig. Arrows (a,b)
denote aggregations of leukocyte nuclei (dark blue). Bar equals 100 micron. Specificity control for anti-B220 staining of a section from a
untreated mouse lacrimal gland (g); the area of the inset box in (g) is shown at higher magnification in (h) or an adjacent section stained
without the primary antibody (i); arrowhead marks same location in (h,i). FACS analysis of leukocytes isolated from lacrimal glands of mice
treated with MOPC-21 control antibody (n = 8 glands) or LTBR-Ig (n = 8 glands) (j). Mean and standard deviation of total CD45 positive
leukocytes, total number of B220 positive cells (B-cells) and of CD3 positive cells (T-cells) are indicated for each treatment type. This experiment
was repeated four times. Statistical significance was calculated by two-tailed T-test. FACS, flow cytometry; LTBR-Ig, lymphotoxin-beta receptor-
mouse immunoglobulin (Fc), NOD, non-obese diabetic.
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that in one year-old mice (n = 4), the leukocyte aggre-
gates after immunofluoresence staining for B-cells
(blue), T-cells (red) and FDC (green), were often seen to
be well organized, with well defined T-cell and B-cell
zones. These hallmarks of tertiary lymphoid tissue for-
mation (TLT) were observed in less than 10% of lacri-
mal-gland infiltrates of the mice aged 8 to 20 weeks that
were used in this study.
The majority of lymphocytes present in lacrimal glands
of mice 16 weeks of age were B-cells. After immunostain-
ing with anti-B220 and detection by deposition of insolu-
ble DAB substrate, B-cells were visible as massive clusters
of dark brown stained cells, shown in Figure 1d, e. Specifi-
city of the immunostaining pattern for B220 was con-
firmed by omitting primary antibody, shown in Figure 1g
to 1i. As seen in Figure 1f, the aggregates of B-cells present
in lacrimal glands were much smaller after treatment with
LTBR-Ig. T-cells were also present in the lymphocyte
aggregates (approximately 20% of leukocytes) but they
were rarely found clustered together (data not shown).
Staining for anti-CD3 by immunoperoxidase in paraffin
sections, as well as immunofluorescence staining in frozen
sections (data not shown) revealed that T-cells in lacrimal
glands were most often observed as scattered, individual
T-cells or occasionally were clustered in small groups of
cells (<10 cells). This distribution of T-cells differs from
that observed in the submandibular glands of female NOD
mice of the same age, in which were found larger and
more tightly grouped T-cells typical of organized TLT
[26]. Interestingly, in the lacrimal glands of 1 year old
male NOD mice (n = 4), distinctly segregated T-cell and
B-cell areas were frequently observed, suggesting that
more classical tertiary lymphoid follicles eventually do
form in the lacrimal glands, as illustrated in Additional
File 1b.
To quantify changes in the composition of the leukocyte
infiltrates present in lacrimal glands after an 8-week treat-
ment with LTBR-Ig, leucocytes were isolated from lacri-
mal glands and subjected to multicolor FACS analysis.
As shown in Figure 1j, treatment with LTBR-Ig reduced
the number of CD45 positive cells (n = 8 glands) by 3.2-
fold compared to controls, specifically from approximately
8 × 106 per gland to approximately 3 × 106 per gland,
respectively. A preferential reduction in the number of B-
cells by LTBR-Ig treatment was observed, with a 4.8-fold
reduction of B-cells (B220 positive) compared to only a
2-fold reduction of T-cells (CD3 positive), shown in Figure
1j. This result suggested that a large part of the mechan-
ism(s) underlying the effect of LTBR-Ig antagonism on
lymphocyte accumulation in lacrimal glands might be
B-cell specific.
Three treatment regimens were used in our study, an
early, preventative or prophylactic regimen (8 to 16
weeks of age), and two delayed or therapeutic regimens
(10 to 20 weeks and 14 to approximately 22 weeks of
age). All treatment regimens caused similar reductions
(approximately 3-fold) in the total number of leukocytes
in lacrimal glands of mice treated with LTBR-Ig, and
particularly of B-cells, as shown for the prophylactic (8
to 16 weeks) regimen, in Figure 1 and for the therapeu-
tic treatment regimen (14 to 22 weeks) in Additional
File 3a.
FACS analysis of leukocytes in lacrimal infiltrates, blood
and spleen
To gain more insight into the abundance of various cell
types present in lacrimal glands and the effect of LTBR-
Ig treatment, we subjected leukocytes from lacrimal
glands, spleen and blood to additional FACS analyses in
mice 20 weeks of age, after a 10-week treatment with
either or LTBR-Ig or the MOPC-21 control protein.
Since others had reported an association of marginal
zone B-cells with sialadenitis in a BAFF transgenic
mouse model, we carefully examined this B-cell subset
first [31,32]. The marginal zone B-cell (MZB) subset
(B220-hi/CD21-hi/CD23-lo) was examined by gating on
B220 and displaying CD21 and CD23 in a dot plot, as
illustrated for splenocytes in Figure 2a. In the NOD
mouse lacrimal glands, MZB were rare compared to
spleen; a comparison of representative FACS dot-plots
of splenic MZB and lacrimal gland MZB is shown in
Additional File 3. As shown in Figure 2b, the mean per-
centage of MZB in lacrimal glands was considerably
lower than that in spleen; and the majority of B-cells in
lacrimal glands were conventional follicular B-cells
(approximately 80%) as shown in a representative exam-
ple in Additional File 3. As expected, in spleen the per-
centage of MZB was reduced by LTBR-Ig treatment, but
the abundance of MZB was not affected in lacrimal
glands, shown in Figure 2b. The reduction of MZB in
spleen is a hallmark of LTBR-Ig antagonism [33,34] and
confirmed that the LTBR-Ig chimeric protein antagonist
had remained biologically active for the 10 weeks of
administration. B220 positive cells that also expressed
CD5 (putative B1-cell subset) constituted <2% of the
B220 positive cells (data not shown).
The percentage of B-cells among all leukocytes iso-
lated from the lacrimal glands was reduced about 5-fold
to 11% (+/- 2.0) when mice were treated with LTBR-Ig,
compared to 52% (+/- 6.2) for mice treated with
MOPC-21 control protein, as shown in Figure 2c (P =
0.001). The opposite trend was found in the peripheral
blood of the mice treated with LTBR-Ig, where the per-
centage of B-cells was higher compared to controls,
shown in Figure 2c. Treatment with LTBR-Ig altered
the ratio of B-cells to T-cells in the lacrimal glands
approximately 2-fold (p = 0.01), but did not change the
ratio in the spleen, as shown in Figure 2d.
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Figure 2 FACS analysis of leukocytes in lacrimal glands, spleen and blood. FACS analysis was performed on leukocytes from lacrimal-
glands, spleen and in peripheral blood taken from NOD mice after treatment from 10 to 20 weeks with either MOPC-21 control protein (n = 7
mice) or LTBR-Ig (n = 8 mice), as indicated. Gating for marginal zone B-cells or MZB (B220+/CD23-int/CD21-hi) is depicted for spleen cells (a)
with the MZB region indicated (red circle, third dot-plot). Treatment with LTBR-Ig reduced MZB in spleen but not lacrimal glands (b), reduced
the percent of B-cells approximately 4-fold, whereas the percentage of B-cells in peripheral blood increased (c), reduced the B-cell to T-cell ratio
in lacrimal glands (d) and reduced the percentage of CD11c cells among non-T non-B-cells (e). Similar experiments (treatment 8 - 16 weeks)
were performed at least four times. LTBR-Ig; lymphotoxin-beta receptor-mouse immunoglobulin (Fc) chimeric inhibitor; MZB, marginal zone B-
cell; NOD, non-obese diabetic.
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Significant numbers of CD11c-positive cells were pre-
sent in lacrimal glands of the male 20-week-old NOD
mice, as shown in Figure 2e. The percentage of CD11c-
positive cells in lacrimal glands, expressed relative to all
cells that were neither CD3-positive T-cells nor B220-
positive B-cells, was reduced from a mean of 44% in lacri-
mal glands of MOPC-21 treated mice to only 15% after
LTBR-Ig treatment, as shown in Figure 3e (P = 0.017).
The possibility that proliferation of B-cells in germinal
center reactions might contribute to the large numbers of
B-cells that accumulated in diseased lacrimal glands was
examined. There was no indication of GL7 staining, a B-
cell activation marker associated with germinal center
(GC) reactions, either by FACS analyses of isolated lym-
phocytes or by immunohistochemical staining of lacrimal
gland tissue sections (data not shown). There also was no
evidence of peanut agglutinin (PNA) staining in lacrimal
glands (data not shown). Finally, the rate of proliferation
of T-cells and B-cells was determined by a 1 hour, in vivo
pulse of bromodeoxyuridine (BrdU) followed by FACS
analysis for BrdU incorporation. The analysis showed only
a very low rate of proliferation (< 1%) in either T- or
B-lymphocytes present in lacrimal glands and lymph
nodes, while a rate of approximately 6% was seen in thy-
mus for T-cells, as shown in Additional File 4. This low
proliferation rate was not altered by the 8-week treatment
of mice with LTBR-Ig.
Lacrimal Gland Gene Expression Analysis
Lacrimal glands from mice that were untreated or treated
with control protein or LTBR-Ig from weeks 8 to 16
were analyzed for differential gene expression. At week
16, using an arbitrary minimum of a 2-fold change, there
were approximately 1,500 differentially expressed genes
after LTBR-Ig treatment when compared to either the
untreated or control protein cohorts. Genes down- or
Figure 3 Reduction of mRNA expression of HEV genes and chemokines by LTBR-Ig. Real-time PCR analysis was performed on total mRNA
isolated from lacrimal glands and lymph nodes from mice after treatment from 10 to 20 weeks with LTBR-Ig or MOPC-21. There were eight
mice in each treatment group. The fold-change for each gene shown here was calculated relative to expression of that gene in healthy lacrimal
glands from 20-week-old female NOD mice (n = 8). A comparison is shown of the effect of each treatment type on genes associated with HEV
(a); adhesion molecules VCAM and MAdCAM (b); homeostatic chemokines (c); and other chemokines (d). The mean fold-change of eight
samples and the standard deviation are plotted. Statistical analysis was by Student’s T-test; P*< 0.05; P**< 0.01; P***< 0.001. HEV, high endothelial
venule; LTBR-Ig; lymphotoxin-beta receptor-mouse immunoglobulin (Fc) chimeric inhibitor; MAdCAM, mucosal adressin/cell adhesion molecule;
NOD, non-obese diabetic; PCR, polymerase chain reaction; VCAM, vascular cell adhesion molecule.
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up-modulated by at least 5 fold are listed in Table 1 and
Table 2. Among the most highly down modulated genes
was Glycam, as expected, based on the ability of LTBR-Ig
to affect the differentiation program that drives HEV
addressin expression in secondary lymphoid organs [6].
The loss of L-selectin mRNA (Sell) expression is assumed
to reflect the reduced entry of L-selectin positive lympho-
cytes into the gland via PNAd and HEV. Expression of a
secreted phospholipase A2 (Pla2g2d) was also reduced
10-fold; this enzyme is selectively produced in lymphoid
tissue and was previously shown to be under LTBR
control [35,36]. Reflecting the reduced size of the leuko-
cyte infiltrate, the expression of a large number of B-cell
related genes as defined using the Immunological Gen-
ome Project database was reduced 5-fold or more by
LTBR-Ig treatment (Igh1 (IgG2a heavy chain), Cxcr5,
Ebf1, Hhex, Fcrl1, Fcer2a, Btk, Cd37, Btla, B3gnt5, Cr2,
Bank1, Cd38, H2-Ob and Ms4a1. Genes that were
increased by more than 80-fold included salivary protein
2 (Spt2), renin 1 (Ren1) and cysteine-rich secretory pro-
tein 3 (Crisp3). Additionally, 13 different kallikrein genes
were highly upregulated along with mucin 10 (Muc10)
Table 1 Lacrimal gland gene expression reduced by treatment of mice with LTBR-Ig compared to control
Gene Fold Change Down
Glycam1 glycosylation dependent cell adhesion molecule 1 29.02
Serpina1b serine (or cysteine) preptidase inhibitor, clade A, member 1b 12.30
Sell selectin, lymphocyte 11.43
Pla2g2d phospholipase A2, group IID 10.53
Igh-1a IgG2a heavy chain 8.47
Faim3 Fas apoptotic inhibitory molecule 3 8.09
Ccl19 CCL19 chemokine 7.67
Cxcr5 C-X-C Chemokine receptor type 5 7.59
Rnase6 ribonuclease, RNase A family, 6 7.19
Clca2 chloride channel calcium activated 2 6.77
Cxcr4 chemokine (C-X-C motif) receptor 4 6.71
Aff3 AF4/FMR2 family, member 3 6.46
Ebf1 early B-cell factor 1 6.42
Rasal3 RAS protein activator like 3 6.34
Hhex hematopoietically expressed homeobox 6.23
Fcrl1 Fc receptor-like 1 6.18
Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide 6.17
Btk Bruton agammaglobulinemia tyrosine kinase 6.12
Cd37 CD37 antigen 6.09
Btla B and T lymphocyte associated 6.07
B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 5.67
Cxcl13 chemokine (C-X-C motif) ligand 13 5.57
Fcrl1 Fc receptor-like 1 5.57
Ubd ubiquitin D 5.54
Fam55c family with sequence similarity 55, member C 5.53
Cr2 complement receptor 2 5.49
Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide 5.39
H2-Ob histocompatibility 2, O region beta locus 5.38
Bank1 B-cell scaffold protein with ankyrin repeats 1 5.36
Stat4 signal transducer and activator of transcription 4 5.26
Ptprc protein tyrosine phosphatase, receptor type, C 5.25
Cd38 CD38 antigen 5.19
Ms4a1 membrane-spanning 4-domains, subfamily A, member 1 5.19
Pde7a phosphodiesterase 7A 5.16
Lrrk2 leucine-rich repeat kinase 2 5.15
Plekha2 pleckstrin homology domain-containing, family A 5.14
Slamf6 SLAM family member 6 5.07
Slc2a3 solute carrier family 2 (facilitated glucose transporter), member 3 5.04
Tcrb-V13 T-cell receptor beta, variable 13 5.00
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and nerve growth factor-beta (Ngfb). The increased
expression of various secretory proteins suggests that
LTBR-Ig triggered increased glandular function and/or
repair. While some of the most regulated genes were dif-
ferentially expressed after only 4 weeks of treatment, the
number of significant changes was much reduced com-
pared to the number after 8-weeks of treatment (data not
shown).
Based on the Affymetrix gene-expression analyses we
examined a few genes by quantitative PCR, as shown in
Figure 3, including the addressin scaffold Glycam1 [37]
and two sulfotransferase enzymes (Chst2 and Chst4)
important in carbohydrate modifications of the adhesion
molecule PNAd [38]. Two additional adhesion-mole-
cules were examined as well, VCAM and MAdCAM. To
avoid introducing confounding parameters due to use of
a different mouse strain or a different age/developmen-
tal stage in the NOD strain, the mRNA level for each
gene in the diseased lacrimal glands of the 20-week old
male mice was compared to the level of expression of
the same gene in the healthy lacrimal glands from
female NOD mice of the same age. Histologic analysis
of lacrimal glands from 14 to 20-week old female mice
revealed only occasional indications of disease, such as
small leukocyte infiltrates, and small B-cell clusters
shown in Additional File 5. The mRNA expression of all
genes we examined was higher in diseased lacrimal
glands of male NOD mice compared to healthy lacrimal
glands of female mice, as shown in Figure 3, and some
genes were extremely highly induced such as GlyCAM
(approximately 3,000-fold) and CXCL9 (approximately
1,000-fold).
While the expression of Glycam1, Chst4, CCL19 was
greatly reduced by LTBR-Ig treatment (Figure 3a and 3c),
expression of Chst2, CXCL13 and CCL21a were only
modestly decreased (approximately 2-fold) when com-
pared to the levels in MOPC-21 treated mice (Figure 3a
and 3c). Expression of MAdCAM, CXCL9 and CXCL12
was not significantly altered (Figure 3b and 3d). MAd-
CAM addressin expression is often under LTBR control,
but in this ectopic follicle setting, MAdCAM was not
induced by disease.
LTBR-Ig reduced CXCL13 protein in lacrimal glands
CXCL13 protein in lacrimal glands increased with age of
the mice, and roughly mirrored the disease progression,
as shown in Figure 4a. Interestingly, CXCL13 protein
was very abundant in highly diseased lacrimal glands
and the amount of CXCL13 per mg tissue equaled and
sometimes exceeded the amount in cervical lymph
nodes (approximately 40 pg/mg; data not shown).
As shown in Figure 4b, LTBR-Ig treatment from 8 to
16 weeks reduced the CXCL13 protein content of lacri-
mal glands approximately 5-fold compared to untreated
Table 2 Lacrimal gland gene expression elevated by treatment of mice with LTBR-Ig compared to control
Gene Fold Change Up
Spt2 salivary protein 2 116.39
Ren1 renin 1 structural 108.03
Crisp3 cysteine-rich secretory protein 3 88.55
Klk1b26 kallikrein 1-related petidase b26 83.06
Klk1b16 kallikrein 1-related peptidase b16 71.72
Abpb androgen binding protein beta 51.14
Klk1b5 kallikrein 1-related peptidase b5 43.58
Klk1b9 kallikrein 1-related peptidase b9 42.18
Klk1b4 kallikrein 1-related pepidase b4 31.05
Klk1b8 kallikrein 1-related peptidase b8 30.37
Klk1b3 kallikrein 1-related peptidase b3 30.26
Muc10 mucin 10, submandibular gland salivary mucin 26.56
Egfbp2 epidermal growth factor binding protein type B 23.63
Klk1b4 kallikrein 1-related pepidase b4 18.95
Klk1b1 kallikrein 1-related peptidase b1 18.63
Smr2 submaxillary gland androgen regulated protein 2 15.83
Klk1b27 kallikrein 1-related peptidase b27 15.45
Klk1b21 kallikrein 1-related peptidase b21 14.58
Abpa androgen binding protein alpha 9.94
Ngfb nerve growth factor, beta 9.06
Klk1b24 kallikrein 1-related peptidase b24 8.59
Egf epidermal growth factor 5.92
Klk1b11 kallikrein 1-related peptidase b11 5.29
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control mice, from a mean of approximately 50 pg/mg to
approximately 10 pg/mg tissue (P < 0.001). The reduction
of mRNA and protein level of CXCL13 in lacrimal glands
by LTBR-Ig is consistent with the approximately 5-fold
reduction of B-cells present in lacrimal glands of LTBR-
Ig treated mice, compared to control mice (Figure 2g). It
is noteworthy that the amount of CXCL13 protein pre-
sent in the diseased salivary glands of female NOD mice
was approximately 10-times less than that of diseased
lacrimal glands (data not shown).
CXCL13 is elevated in sera of Sjögren’s syndrome
patients
The CXCL13 concentration in Sjögren’s patient sera was
measured by ELISA. The mean of the concentration of
CXCL13 in sera from 27 patients diagnosed with primary
Sjögren’s syndrome was significantly higher (170 +/- 23
pg/ml) than that determined for thirty healthy control
sera (92.0 +/- 18.9 pg/ml), as shown in Figure 4c, (P =
0.01). Examination of an independent cohort of sera
from 18 Sjögren’s syndrome patients gave comparable
results (J. Browning, data not shown). Although it is
known that immunoreactive CXCL13 is present in
salivary glands of patients with Sjögren’s syndrome [10],
to our knowledge the amount of CXCL13 in the sera of
patients has not yet been reported [1].
LTBR-Ig reduced HEV in lacrimals
HEV begin to appear in lacrimal glands of male NOD mice
at about 8 weeks of age [22]. Since LTBR blockade reduced
the numbers of HEV in lymph nodes and in diseased sali-
vary glands of female NOD mice [6,23,26], the effect of
LTBR-Ig treatment on the numbers of HEV in lacrimal
glands was examined. Functional HEV react with monoclo-
nal antibody MECA-79 as shown in Figure 5 (a to c). As
illustrated in Figure 5a and 5b, HEV were abundant at 16
weeks of age in the lacrimal glands of untreated mice and
mice treated with MOPC-21, but HEV were virtually
absent from the lacrimal glands of mice treated with
LTBR-Ig, shown in Figure 5c. The HEV content of lacrimal
glands was quantified and expressed as a percent of the
total area of each lacrimal gland. The HEV area was
reduced approximately 25-fold by LTBR antagonism (8 to
16 weeks) to 0.03% (±0.01) compared to 1.05% (±0.19) for
untreated mice and 0.75% (±0.19) for MOPC-21 treated
mice. Similar results were obtained with both the
Figure 4 CXCL13 protein measured by ELISA in mouse lacrimal glands and in sera from Sjögren’s patients. Homogenates made from
individual lacrimal glands (n = 8) were analyzed for CXCL13 protein levels by ELISA (a,b). CXCL13 protein increased with age/disease
progression in lacrimal glands from untreated male NOD mice (a). LTBR-Ig treatment from 8 to 16 weeks reduced CXCL13 content of mouse
lacrimal glands (b). Mean concentration of CXCL13 was significantly elevated in serum samples of Sjögren’s syndrome patients (n = 27) versus
healthy control sera (n = 30) (c). The mean age of Sjögren’s syndrome patients was 57.17 +/- 10.10 years, and for controls was 57.55 +/- 21.17
years. There was one man in each group. ELISA, enzyme linked immunosorbant assay; NOD, non-obese diabetic.
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prophylactic treatment regimen (8 to 16 weeks) and the
therapeutic treatment regimen (14 to 22 weeks), as shown
in Additional File 2b.
LTBR-Ig reduced uptake rate of lymphocytes into lacrimal
glands
To determine if the reduction of HEV content of lacri-
mal glands had functional consequences the rate of lym-
phocyte uptake into glands of control and LTBR-Ig
treated mice was directly measured. CFSE-labeled lym-
phocytes were injected intravenously into recipient mice
that had been treated with either MOPC-21 or LTBR-Ig
from 8 to 16 weeks of age, and the number of CFSE-
labeled cells present in the lacrimal glands following a
20-hour interval was determined by FACS analysis. A
fluorescence-photomicrograph of the appearance of
CFSE-labeled lymphocytes in lacrimal glands of a repre-
sentative LTBR-Ig treated mouse is shown in Figure 5d
in which CFSE-labeled cells appear green (examples are
indicated by arrows) and B-lymphocytes are indicated in
red (anti-B220-APC).
For quantitation of CFSE-labeled cells by flow-cytome-
try, leukocytes were isolated from lacrimal glands and
then stained with a multicolor antibody cocktail con-
taining anti-CD45, anti-CD4, anti-B220 and anti-CD62L.
Live CD45-positive cells were gated and the CFSE-
labeled cells (FITC channel) were detected among cells
isolated from each pair of lacrimal glands. The number
of CFSE-cells/200,000 CD45-positive cells was calculated
and plotted for each group. As shown in Figure 5e, the
uptake rate in mice treated with LTBR-Ig was reduced
approximately three-fold for total CD45 positive cells,
approximately four-fold for T-cells and approximately
seven-fold for B-cells.
For comparative purposes we also measured CFSE-cell
uptake by the cervical lymph nodes. Uptake of CFSE-
labeled lymphocytes by lymph nodes occurred approxi-
mately two times faster than uptake by lacrimal glands,
Figure 5 LTBR-antagonism from 8 to16 weeks reduced the number of HEV in lacrimal glands and the uptake of CFSE-labeled lymphocytes
into lacrimal glands. Immuno-peroxidase visualized HEV (brown) after immunostaining with MECA-79 monoclonal antibody against PNAd in paraffin
sections of lacrimal glands (NT = no treatment) (a-c). The bar in (a-c) indicates 100 μm. Fluorescence photomicrograph of a lacrimal gland with B-cells
(anti-B220, red) and CFSE-labeled cells indicated by arrowheads (CFSE, green) (d). Quantification by FACS-analysis of CFSE-labeled lymphocytes among
all lymphocytes isolated from lacrimal glands or cervical lymph nodes collected from mice (n = 4) that had been treated for 8 weeks with MOPC-21
(open bars) or LTBR-Ig (black bars). Qualitative assessment of ablation of MECA-79 stained HEV by LTBR-Ig treatments was performed more than five
times. Quantitation of CFSE cell uptake was performed twice. CFSE, carboxyfluorescein succinimidyl ester; FACS, flow cytometry; HEV, high endothelial
venule; LTBR, lymphotoxin-beta receptor; LTBR-Ig; lymphotoxin-beta receptor-mouse immunoglobulin (Fc) chimeric inhibitor.
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perhaps because lymph nodes have an intrinsically
greater capacity for capturing naïve lymphocytes com-
pared to the ectopic follicular-structures in diseased
lacrimal glands. As previously reported [6], LTBR-Ig
treatment also reduced the uptake of cells into lymph
nodes, as shown in Figure 5e.
LTBR-Ig Preserved Tear -flow Rate
To assess whether the reduced lymphocytic infiltrates in
lacrimal glands of LTBR-Ig-treated mice was associated
with a reduction in loss of lacrimal gland function, two
parameters related to ocular health were examined, the
rate of tear fluid secretion and the integrity of the ocular
surface. In previous studies in mice, the basal tear fluid
secretion rate was measured for unstimulated lacrimal
glands, as well as after stimulation of the lacrimal glands
to their maximal secretion rate by the systemic adminis-
tration of pilocarpine, a parasympathetic nervous system
agonist. In this study, both methods were used, as
shown in Figure 6a and 6b.
As shown in Figure 6a, the basal tear fluid secretion
rate was significantly greater after LTBR-Ig treatment
for 4 weeks compared to MOPC-21 treated control
mice (P = 0.0002), but after 8 weeks of treatment the
difference was not quite statistically significant (P =
0.056), although a protective trend was apparent.
To measure the pilocarpine stimulated, maximal tear
secretion rate, excess tear fluid that had collected under
the eyelid during the first 5 minutes after injection of
pilocarpine was first removed, and then the amount of
tear fluid that was secreted for the next 10 minutes was
measured. As shown in Figure 6b, mice treated with
LTBR-Ig for 8 weeks secreted more tear fluid than
untreated control mice or control mice treated with
MOPC-21 (P = 0.0001).
LTBR-Ig preserved the integrity of the ocular surface
The integrity of the ocular epithelial surface serves as an
indirect measure of the long-term consequences of net
changes in the protein composition of the tear film, in
combination with the rate/volume of tear fluid secretion.
Application of aqueous FITC is a simple and effective
way to assess the condition of the ocular surface. In this
analysis, perfectly intact epithelium does not bind FITC.
In contrast, defects in the ocular surface epithelial cell
layer allow FITC to access components of the underly-
ing cell layers and extra-cellular matrix where the FITC
then can adhere and is visible under UV-enriched illu-
mination with a cobalt blue filter. Using an established,
semi-quantitative scoring system, FITC staining of the
corneal/conjunctival surface was evaluated by slit-lamp
microscopic eye examination of each eye (n = 10), and
the corneal and conjunctival areas were scored on a
scale of 1 to 4 (shown in Additional File 6) by an
observer unaware of the type of treatment given to each
mouse. The cornea was defined as the region directly
over the center of the eye and extending to the peri-
meter of the pupil (red circle, Figure 7a), and the con-
junctiva was the remainder of the ocular surface.
Selected examples of the extremes of the range of FITC
staining are shown in Figure 7a, in which a zero score is
illustrated with an LTBR-Ig-treated mouse and a maxi-
mal score of 4 is illustrated with an untreated mouse.
As shown in Figure 7b, LTBR-Ig treatment of mice for
8 weeks resulted in significantly lower scores for FITC
staining for both conjunctiva (P = 0.0001) and cornea
(P = 0.0005), reflecting less damage to the ocular epithe-
lial surface.
Discussion
In this study, antagonism of the LTBR axis greatly
reduced CXCL13 in diseased extra-orbital lacrimal
glands and profoundly reduced the B-lymphocyte bur-
den in the glands. These effects of LTBR antagonism on
B-cells and CXCL13 are especially interesting in light of
the recent recognition of the importance of B-cells in
Sjögren’s syndrome. Certain B-cell subsets found in the
glands of Sjögren’s patients, possibly due to aberrant
expression of B-cell growth and differentiation factor
BAFF, have been proposed to contribute to the patho-
genesis in Sjögren’s [39-41]. That B-cells contribute
greatly to other autoimmune diseases has been verified
clinically, as exemplified by the success of B-cell deple-
tion therapy for treatment of rheumatoid arthritis [42].
Recently, a report of a double blind, randomized clinical
trial of B-cell depletion by rituximab showed beneficial
effects in Sjögren’s patients suggesting that B-cell tar-
geted therapies may be useful to treat Sjögren’s syn-
drome as well[43].
The health of the ocular surface depends on diverse
factors, including tear osmolarity, the protein/proteogly-
can constituents of tear fluids, and the volume of tear
fluid delivered to the ocular surface. Tear fluid contains
over 400 protein constituents that undoubtedly play
important, although currently poorly defined roles in cor-
neal and conjunctiva epithelial integrity [44,45]. In the
male NOD mouse, within the first 6 weeks of age lacri-
mal glands undergo markedly altered gene expression
[19,20], including elevated expression of cathepsin,
increased extra-cellular matrix degradation and altered
lipid homeostasis [46,47]. These changes precede the
massive accumulation of leukocytes that culminates in
overt exocrinopathy by 12 to 16 weeks of age [48,49]. In
this study, differential gene expression analysis with Affy-
metrix gene arrays showed that antagonism of the LTBR-
axis altered the expression of a wide variety of genes
related to lymphocyte trafficking, lymphocyte function
and lacrimal gland function, and these changes coincided
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with improvement in tear fluid secretion and ocular
integrity, two measures of overall ocular health. While
the precise mechanism(s) of action are not yet clear, the
net result of LTBR antagonism was a diminution of the
loss of tear production by lacrimal glands and partial pro-
tection from loss of the integrity of the ocular surface.
The beneficial effects of LTBR antagonism reported
here are likely linked to diverse factors. It is the com-
bined effect of reduced tear fluid volume and the altered
composition of tear fluid due to lacrimal gland disease
that results in damage to the epithelial cell layer of the
ocular surface. The reduced delivery of protective anti-
bodies and of growth factors such as epidermal growth
factor (EGF) and nerve growth factor (NGF), which
have been implicated in corneal epithelial homeostasis,
are thought to contribute to loss of ocular surface integ-
rity [50]. Administration of LTBR-Ig spared some of
these protein factors of tear fluid from disease-driven
down regulation. For example, LTBR-Ig treatment
diminished the disease associated losses in mRNA
Figure 6 LTBR-Ig enhanced the volume of tear-fluid secreted by lacrimal glands. Mice were treated from age 8 to 16 weeks with LTBR-Ig
(circles), with MOPC-21 control antibody (triangles), or were left untreated (squares). The amount of tear fluid secreted for each eye of each
mouse was determined by insertion of a Zone-Quick phenol impregnated thread under the eyelid at the medial canthus. The length of thread
wetted by capillary action in 30 seconds was measured and plotted (a). The amount of tear fluid secreted was determined at age 12 weeks
(after 4 weeks of treatment) and at 16 weeks of age (after 8 weeks of treatment), as indicated on each graph in (a). The rate of tear fluid
secretion was also determined in the presence of pharmacologic stimulation. In a separate experiment, after 8 week treatments as indicated,
each mouse was injected with pilocarpine to maximally stimulate tear fluid secretion, and after 5 minutes, the amount of tear fluid secreted by
each eye during the next 10 minutes was measured by wetting of a Zone-Quick thread placed under the lid (b). Statistical analysis was by the
two-tailed Student’s test. P*< 0.05; P**< 0.01; P*** < 0.001. This type of experiment was performed four times. LTBR-Ig; lymphotoxin-beta
receptor-mouse immunoglobulin (Fc) chimeric inhibitor.
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expression of NGF (approximately 9-fold higher than in
control antibody treated mice), EGF (approximately 6-
fold higher), mucin 10 (approximately 30-fold higher)
and EGF-binding protein (approximately 24-fold higher)
and may have helped to maintain the integrity of the
ocular surface, as these proteins may have roles in cor-
neal epithelial cell renewal (see Table 1). Increased
repair of the ocular surface and the gland itself (that is,
sustained growth factor expression) may be factors in
the beneficial outcome of LTBR blockade. Future studies
are planned to evaluate this possibility more directly.
The gene expression patterns we observed by Affyme-
trix chip assay clearly reflected the profound reduction
in the number of leukocytes in lacrimal glands after
antagonism of the LTBR axis for 8 weeks. Many genes
related to B-cell signaling pathways that are elevated by
disease progression were reduced by LTBR-Ig treat-
ments (data not shown). The ability of LTBR-Ig to
Figure 7 LTBR-Ig treatment reduced the loss of epithelial integrity of conjunctiva and cornea. Selected examples of the appearance of
mouse eyes 5 minutes after applying a 5 μl drop of FITC-PBS (a). Eyes of anesthetized mice were illuminated with Cobalt-blue filtered light and
observed and photographed though a slit-lamp microscope (a). Note that the bright green outline of the eye is pooled excess FITC-PBS and
does not indicate epithelial damage. An example of a corneal score of zero for an LTBR-Ig treated mouse (left) and a score of 4 for an untreated
mouse (right) is shown, where the red circle in (a) indicates the region defined as the cornea. Mice were treated from age 8 to 16 weeks with
LTBR-Ig (circles in b), were left untreated (squares in b), or were treated with MOPC-21 control antibody (triangles in b). The scores for the
conjunctiva (left graph) and the cornea (right graph) for one eye of each mouse (contra-lateral to the eye used to measure tear secretion) were
plotted and the mean score indicated (b). This experiment was performed twice. FITC, fluorescein isothyocyanate; LTBR-Ig; lymphotoxin-beta
receptor-mouse immunoglobulin (Fc) chimeric inhibitor; PBS, phosphate-buffered saline.
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prevent and reverse the differentiation of venules near
the leukocyte infiltrates to HEV was also reflected in the
gene expression data, with Glycam1 and Chst4 being
profoundly reduced, resulting in a co-ordinate reduction
of L-selection expression, probably because of reduced
entry of naïve lymphocytes into lacrimal glands. Uptake
of fluorescent labeled lymphocytes into lacrimal glands
was reduced several fold in mice treated with LTBR-Ig
compared to controls, demonstrating functional conse-
quences of the effects of LTBR-Ig treatment on HEV.
Thus, a major action of LTBR antagonism was the
reduction of the rate of entry of lymphocytes into lacri-
mal glands probably due to the virtual elimination of
HEV that expressed PNAd.
The tight association between the presence of HEV and
B-cell accumulation is consistent with the notion that HEV
formation is an early event in TLT formation. However, in
diseased lacrimal glands, the lymphoid cell aggregates
appear suspended in an intermediate or immature state
since they were slow to acquire the micro-architecture of
mature TLT, such as well-segregated T-cell areas and B-
cell areas with associated FDC networks. This immature
state is very apparent when compared to submandibular
glands in female NOD mice [26]. The factors that prevent
or delay the organization of the lymphocyte aggregates in
lacrimal glands are not understood. However, one striking
difference was a paucity of lymphatic vessels near lymphoid
aggregates of lacrimal glands compared to the TLT of dis-
eased submandibular glands in female NOD mice. LYVE-1
immunoreactive lymphatic vessels were abundant near
TLT in submandibular glands of female mice, but lympha-
tic vessels were essentially absent from the perimeter of the
large B-cell aggregates in diseased lacrimal glands (data not
shown). Lymphatic vessels have been reported to be rela-
tively scarce in lacrimal glands, which may make any lym-
phangiogenic response in lacrimal glands less robust than
in salivary glands[51]. Lymph angiogenesis is tightly linked
to mature TLT development, as demonstrated in an
experimental model of Hashimoto’s disease in the thyroid
where robust lymph angiogenesis was driven primarily by
T-cells during development of ectopic follicles [23]. Inter-
estingly, it is known that B-cells exit lymph nodes in part
by directly entering lymphatic vessels in the cortex of
lymph nodes [52]; a difficulty in exiting lacrimal glands via
lymphatic vessels in a similar fashion could contribute to
accumulation of B-cells. We speculate that high levels of
CXCL13 and the lack of robust lymph angiogenesis in
lacrimal glands contribute to limited egress of B-cells from
glands.
A discordance was noted between the modest (approxi-
mately two-fold) down-modulation of CXCL13 mRNA
and the approximately five-fold reduction of CXCL13
protein in lacrimal glands after 8 weeks of LTBR-Ig treat-
ment. One possibility is that LTBR-Ig treatment affects
elements on the extracellular matrix and peri-cellular
matrix of HEV that retain CXCL13 in the microenviron-
ment. Interestingly, lacrimal glands contained approxi-
mately 10 times more CXCL13/mg tissue measured by
ELISA than did salivary glands of female NOD mice of
comparable age (data not shown). This was particularly
surprising as FDC networks, a known source of CXCL13
production [53], were abundant in salivary gland TLT
[26] but were rare in lacrimal glands. The source(s) of
the large amount of CXCL13 produced during the course
of lacrimal gland disease remains under investigation.
Early in situ hybridization studies in human salivary
gland biopsies from Sjögren’s patients have suggested
that ductal epithelial cells may produce CXCL13 [54].
Reports have been made that monocytic cells [55] and
CD11c dendritic cells [56,57] are potential sources of
CXCL13, and we will investigate this possibility in future
studies. Other possibilities include follicular-B helper T-
cells which make CXCL13 in the follicles of secondary
lymphoid tissues [53], as well as stromal organizer cells
which may be present where TLT development is occur-
ring [4,58,59]. Yet another possibility is the induction of
CXCL13 expression in macrophages by biglycan, a bypro-
duct of degradation of the extra-cellular matrix known to
occur in diseased lacrimal glands [46,60].
Conclusions
These data suggest that antagonism of LTBR may be
effective as a therapy to treat the dry eye aspect of Sjög-
ren’s syndrome. The efficacy is likely due to the com-
bined effects of the modulation of mRNA expression of
a number of functional and disease associated genes in
the lacrimal gland, a reduction of CXCL13 protein in
lacrimal glands, virtual elimination of HEV in lacrimal-
glands and reduced lymphocyte uptake by diseased lacri-
mal glands. Overall, LTBR antagonism produced benefi-
cial effects on tear fluid secretion and the integrity of
the ocular surface. These therapeutic effects were
achieved at a stage of disease that preceded the full
organization of the lymphocyte aggregates into func-
tional tertiary lymphoid follicles, suggesting that mere
reduction of the lymphocyte burden was sufficient to
protect lacrimal gland function. Elucidation of the
detailed mechanisms responsible for these beneficial
effects awaits additional studies.
Additional material
Additional File 1: Histology and fluorescence imaging of diseased
lacrimal-glands. H+E stained paraffin tissue section of a large leukocyte
aggregate in the lacrimal-gland of a 16-week- old male NOD mouse (a).
Overlay of fluorescence photomicrographs of a frozen section of a
lacrimal gland from a 52-week-old male NOD mouse, after
immunostaining with anti-CD3 (red), anti-B220 (blue) and anti CD21/35
(green) (b). Note that highly developed and tightly clustered T-cell areas
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are present (red) and an example is shown in the inset of a small FDC-
network stained by anti-CD21/35 (green). Bar equals 100 μm.
Additional File 2: Delayed LTBR-Ig treatment (14 to 22 weeks)
reduced infiltrates and HEV in lacrimal glands. Photomicrographs of
paraffin tissue sections of lacrimal glands stained with H&E (a, upper) to
show leukocyte aggregates or by monoclonal antibody MECA-79,
immuno-peroxidase and DAB substrate (brown) to show HEV (a, lower).
Note representative images of the appearance of lacrimal glands at the
start of treatment (14 weeks) and after treatment (22 weeks) with MOPC-
21 (a, upper right) or LTBR-Ig (a, lower right). Quantification of the
percent of the total area of lacrimal-gland examined that is occupied by
HEV (top graph) and the number/unit area of HEV (lower graph) with the
effect of treatment with MOPC or LTBR-Ig versus untreated mice is
indicated on the graph. The mean of 20 measurements taken from tissue
sections from five mice is plotted with the standard deviation. Note the
5-fold reduction in HEV content by LTBR-Ig treatment.
Additional File 3: FACS analysis plots and gating for MZB of
lymphocytes from spleen and lacrimal glands. Representative plots
are shown for cells isolated from spleen (left panel) and from lacrimal
glands (right panel) as indicated, after staining for B220, CD4, CD8, CD21
and CD23. Plots shown for cells from each organ are (counterclockwise):
forward and side scatter (upper left), ungated cells B220 and CD4+CD8
combined (lower left), gated first on live lymphocytes then B220 and
CD4+CD8 combined (lower right), gated on B220-positive cells then
CD23 and CD21 (upper right). Gates for marginal zone B-cells (MZB) and
follicular B-cells (FB) are indicated. Note that MZB are much more
abundant in spleen (approximately 17%) than in lacrimal glands
(approximately 3%) in the representative analyses shown. The vast
majority of B-cells in either organ are follicular B-cells, for spleen
approximately 73% and for lacrimal glands approximately 79%. Mice
were treated from 8 to 16 weeks of age.
Additional File 4: Cell proliferation assessed by BrdU incorporation
in thymus, lymph nodes and lacrimal glands. Mice were treated from
8 to 16 weeks with LTBR-Ig (n = 4) or MOPC-21 (n = 4) then BrdU was
injected one hour before euthanasia. Lymphocytes were isolated from
thymus, pooled cervical lymph nodes and lacrimal glands, and were
stained with fluorescent-conjugated ant-iCD45, anti-BrdU, anti-B220, and
anti-CD3 and then analyzed by flow cytometry. The percentage of T-cells
(red columns) and B-cells (blue columns) that had incorporated BrdU
were plotted for thymus (left), cervical lymph nodes (center) and lacrimal
glands (right).
Additional File 5: Comparison of female and male lacrimal-gland B-
cell infiltrates and HEV content. Lacrimal glands were collected from
17 week old male and female mice as indicated (n = 5) and frozen tissue
sections were stained with anti-B220 for B-cells (top) and adjacent tissue
sections were stained with MECA-79 for PNAd expressed on HEV
(bottom) by immunoperoxidase and DAB substrate development
(brown). Arrows (top left) indicate two representative, small, B-cell
aggregates observed in lacrimal glands from female mice. Lower
micrographs are higher magnification images of the same areas marked
by black rectangles in upper micrographs, on tissue sections stained with
MECA-79 to visualize PNAd-positive HEV. Arrow in lower left image marks
the only HEV observed associated with the small B-cell aggregate in the
representative lacrimal gland from a female mouse.
Additional File 6: Slit-lamp microscope images of examples of FITC
staining of eyes of mice. Mice were lightly anesthetized and a drop of
aqueous FITC placed onto the ocular surface and the eyelids manually
closed to spread FITC over the entire surface. Mice awakened to blink
naturally, and were anesthetized again after 5 minutes for examination of
the entire ocular surface by slit-lamp microscopy. Photographs were
taken through a slit-lamp microscope using Cobalt-blue filtered light.
Representative examples of each score given (0-4) are shown as
indicated on the graph. A score of 0 was for no damage visible and a
score of 4 was given for severe damage to the epithelium, reflected by
the amount of FITC staining of the eye surface. Note that the very bright
green at the perimeter of the eye is pooled, excess FITC and does not
indicate ocular damage.
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